Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03592472
Other study ID # XYN-602
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date July 17, 2018
Est. completion date June 30, 2025

Study information

Verified date January 2024
Source Xynomic Pharmaceuticals, Inc.
Contact Sophia Paspal, Ph.D.
Phone 6104055974
Email sophia.paspal@xynomicpharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).


Description:

In this randomized, Phase 3, double-blind, placebo-controlled study, patients will be randomized 2:1 to receive either a combination of pazopanib plus abexinostat or pazopanib plus placebo. At the time of disease progression, patient treatment assignment will be unblinded, and those patients randomized to the pazopanib plus placebo treatment arm will have the option of crossing over to receive treatment with a combination of pazopanib plus abexinostat. After providing written informed consent, patients will be screened for study eligibility within 28 days before their first dose of study drug. After screening assessments, patients who are eligible for inclusion in the study will be randomized and receive their first dose of study drug on Cycle 1 Day 1 (C1D1), within 7 days of randomization. A treatment cycle is 28 days in length. Patients may continue to receive study drug until any of the following events: the development of IRC-verified radiographic progression as assessed by RECIST version 1.1, clinical disease progression, unacceptable toxicity, another discontinuation criterion is met, withdrawal of consent, or closure of the study by the sponsor. No maximum duration of therapy has been set.


Recruitment information / eligibility

Status Recruiting
Enrollment 413
Est. completion date June 30, 2025
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: To be enrolled in the study, patients will be required to meet all of the following criteria: - Patients aged = 18 years at time of study entry. - Patients have histologically confirmed RCC with clear cell component. - Patients have locally advanced and unresectable or metastatic disease. - Measurable disease as assessed only by the investigator (not verified by IRC) according to RECIST version 1.1. - Patients must not have had any prior vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor treatment in either (neo)adjuvant or locally advanced/metastatic setting. Up to 1 line of prior cytokine or immune checkpoint inhibitor treatment is allowed in either the (neo)adjuvant or metastatic setting provided screening scans indicate progressive disease (PD) during or following completion of treatment. - Patients have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Patients have adequate baseline organ function. - Patients have adequate baseline hematologic function - Patient must be at least 2 weeks from last systemic treatment or dose of radiation prior to date of randomization. Exclusion Criteria: Patients who meet any of the following criteria at Screening will not be enrolled in the study: - Has persistent clinically significant toxicities (Grade = 2; per NCI CTCAE version 5 from previous anticancer therapy (excluding alopecia which is permitted and excluding Grades 2 and 3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the investigator, and can be managed with available medical therapies). - Has untreated central nervous system (CNS) metastases. Patients with treated CNS metastases are eligible provided imaging demonstrates no new or progressive metastases obtained at least 4 weeks following completion of treatment. CNS imaging during Screening is not required unless clinically indicated. - Has an additional malignancy requiring treatment within the past 3 years. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, and non-muscle invasive urothelial carcinoma. - Poorly controlled hypertension, defined as systolic blood pressure = 160 or diastolic blood pressure = 100 mmHg. Use of anti-hypertensives and rescreening is permitted. - A new pulmonary embolism or deep venous thrombosis diagnosed within 3 months prior to randomization. - Has a QTcF interval > 480 msec. - New York Heart Association Class III or IV congestive heart failure. - Use of prohibited medication within 7 days or 5 half-lives, whichever is shorter, prior to first dose of study drug.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pazopanib
All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
Abexinostat
The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
Other:
Placebo
The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.

Locations

Country Name City State
China Beijing Cancer Hospital Beijing
China Zhongshan Hospital Affiliated to Fudan University Shanghai
Italy Fondazione del Piemonte per l'Oncologia_Istituto di Candiolo, IRCCS_ Oncologia Medica Candiolo
Italy A.O. Cannizzaro_UOS Oncologia Medica Catania
Italy IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) UO Oncologia Medica Meldola (FC)
Italy Istituto Europeo di Oncologia_Unità Oncologia Medica Urogenitale e Cervico Facciale Milano
Italy Istituto Nazionale dei Tumori-Fondazione Pascale- SC Oncologia Medica Napoli
Italy Azienda Ospedaliero-Universitaria Maggiore della Carità Novara_SC Oncologia Medica Novara
Italy Istituti Clinici Scientifici Maugeri Spa-SB_ UO Oncologia Medica Pavia
Italy Azienda Ospedaliero Universitaria Pisana_ UO Oncologia Medica Universitaria Pisa
Italy Fondazione Policlinico Universitario A. Gemelli, U.O.C. Oncologia Medica Roma
Korea, Republic of National Cancer Center - Center For Prostate Cancer Goyang-si
Korea, Republic of CHA Bundang Medical Center, CHA University Seongnam-si
Korea, Republic of Asan Medical Center - University of Ulsan College of Medicin Seoul
Korea, Republic of Samsung Medical Center - Hematology-Oncology Seoul
Korea, Republic of Severance Hospital, Yonsei University Health System - Medical Oncology Seoul
Poland Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny Brzozow
Poland Szpitale Pomorskie Sp. z o.o. Oddzial Onkologii i Radioterapii Gdynia
Poland Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o. Oddzial Onkologii Klinicznej z Pododdzialem Dziennym Krakow
Poland Clinical Research Center Sp. z o.o., Medic-R Sp. K. Poznan
Spain H.G.U. de Elche Elche
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario Fundación Jiménez Díaz Madrid
Spain H.U. Virgen de la Victoria Málaga
United States St. Luke's Hospital Easton Pennsylvania
United States Precision Cancer Research/Dayton Physicians Network - Treatment Kettering Ohio
United States Northwell Health/Monter Cancer Center Lake Success New York
United States Norton Cancer Institute, Norton Healthcare Pavilion Louisville Kentucky
United States Ochsner Clinic Foundation New Orleans Louisiana
United States GU Research Network/Urology Cancer Center Omaha Nebraska
United States Nebraska Cancer Specialists Omaha Nebraska
United States University Of UA Cancer Center(UACC)/DH-SJHMC Phoenix Arizona
United States Oregon Health and Science University Portland Oregon
United States Mainstreet Physicans Care Rochester New York
United States University of California Davis Comprehensive Cancer Center Sacramento California
United States UCSF Helen Diller Family Comphrensive Cancer Center - Hemato San Francisco California
United States Medical Oncology Associates, PS (dba Summit Cancer Centers) Spokane Washington
United States HOPE Cancer Center of East Texas Tyler Texas

Sponsors (1)

Lead Sponsor Collaborator
Xynomic Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  China,  Italy,  Korea, Republic of,  Poland,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival (PFS) To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assessed by blinded Independent Review Committee (IRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. From randomization date to date of first documentation of progression OR death (up to approximately 4 years).
Secondary PFS by investigator assessment according to RECIST version 1.1. To compare the PFS between treatment arms by investigator assessment. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assessed by IRC according to RECIST version 1.1. From randomization date to date of first documentation of progression OR death (up to approximately 4 years).
Secondary Overall survival (OS) OS is defined as the interval between date of randomization and date of death. The main objective was to compare the OS between treatment arms by investigator assessment. From progression or end of study, every 3 months follow up until death, patient withdrawal from study follow-up, or study closure, whichever occurs first (up to approximately 4 years).
Secondary Adverse events by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 To characterize the safety profile of pazopanib in combination with abexinostat. From Day 1 until end of treatment visit (up to approximately 4 years).
Secondary Objective response rate (ORR) ORR is defined as the proportion of patients with objective evidence of CR or PR by RECIST version 1.1. The main objective was to compare the ORR between treatment arms by investigator assessment. Screening, Cycle 3 Day 1 (C3D1), Cycle 5 Day 1 (C5D1), Cycle 7 Day 1 (C7D1), and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
Secondary Duration of response (DOR) DOR is defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause by RECIST version 1.1. The main objective was to compare the DOR between treatment arms by investigator assessment. Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
Secondary ORR by RECIST version 1.1 in cross-over patient population To describe the ORR in patients who cross over to receive pazopanib plus abexinostat at the time of disease progression on pazopanib monotherapy by investigator assessment. Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
Secondary DOR by RECIST version 1.1 in cross-over patient population To describe the DOR in patients who cross over to receive pazopanib plus abexinostat at the time of disease progression on pazopanib monotherapy by investigator assessment. Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years).
Secondary Mean change from Baseline in Functional Assessment of Cancer Therapy Kidney System Index (FKSI-19) scores To assess the impact of pazopanib with or without abexinostat on disease-related symptoms and health-related quality of life (QoL) by investigator assessment. QoL will be assessed by measuring change from baseline in FKSI-19. The FKSI-19 assesses disease-related symptoms experienced in the past 7 days. Patients are asked to respond to 12 questions ("I have a lack of energy," "I feel pain," for example) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 48). First day of treatment Cycle1, Cycle 2, Cycle 6 (each cycle is 28 days in length) until end-of-treatment visit (up to approximately 4 years).
Secondary Mean change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT-F) scores To assess the impact of pazopanib with or without abexinostat on disease-related symptoms and QoL by investigator assessment. QoL will be assessed by measuring change from baseline in FACIT-F. The FACIT-F scale measures QoL experienced in the past seven days. The measurement consisted of 5 domains (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns) assessed on a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). First day of treatment Cycle1, Cycle 2, Cycle 6 (each cycle is 28 days in length) and at end-of-treatment visit (up to approximately 4 years).
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04987203 - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Phase 3
Recruiting NCT06391879 - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Completed NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Phase 2
Terminated NCT04088500 - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Phase 2
Completed NCT05070637 - Circulating Tumor Cell Reducing No-touch Nephrectomy N/A
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Not yet recruiting NCT06049030 - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01358721 - Phase I Biomarker Study (BMS-936558) Phase 1
Active, not recruiting NCT04503148 - Anesthesia and Cancer Study: Renal Cell Carcinoma N/A
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Not yet recruiting NCT05808608 - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma Phase 1/Phase 2
Withdrawn NCT03323710 - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma Phase 2
Not yet recruiting NCT02787915 - DC1s-CTL Cellular Therapy for Renal Cell Carcinoma Phase 1/Phase 2